KU-60019: Selective ATM Kinase Inhibitor for Glioma Radiosensitization

Executive Summary: KU-60019 is a selective ATM kinase inhibitor (IC50: 6.3 nM) with 270-fold and 1600-fold higher selectivity over DNA-PK and ATR, respectively (APExBIO product information). This compound robustly radiosensitizes both wild-type and mutant p53 glioma cells by disrupting DNA damage response and prosurvival signaling pathways. KU-60019 impairs glioma cell migration and invasion in a dose-dependent manner, and suppresses tumor growth in vivo when paired with radiation treatment. Its solubility profile and storage conditions make it highly practical for experimental workflows in oncology research.

Biological Rationale

The ataxia telangiectasia mutated (ATM) kinase is a serine/threonine kinase integral to the detection and repair of DNA double-strand breaks. Activation of ATM initiates a cascade involved in cell cycle checkpoint control, DNA repair, and prosurvival signaling via AKT and ERK pathways (Qin et al., 2024). In glioma, ATM overactivation contributes to resistance against DNA-damaging therapies, making selective inhibition an attractive strategy for radiosensitization.

Mechanism of Action of KU-60019

KU-60019 inhibits ATM kinase activity with high potency (IC50 = 6.3 nM), demonstrating 270-fold selectivity over DNA-dependent protein kinase (DNA-PK) and 1600-fold over ATR kinase (APExBIO). Upon ATM inhibition, cellular DNA repair capacity is compromised, leading to enhanced sensitivity to radiation-induced damage. KU-60019 also suppresses the phosphorylation of downstream effectors involved in cell survival, including AKT and ERK, thereby potentiating cytotoxic effects in glioma cells.

Evidence & Benchmarks

• KU-60019 exhibits an in vitro IC50 of 6.3 nM against ATM kinase, with a selectivity ratio of 270 for DNA-PK and 1600 for ATR (APExBIO).
• Radiosensitization is observed in both p53 wild-type (U87) and p53 mutant (U1242) glioma cell lines at concentrations as low as 3 μM (detailed mechanism article).
• KU-60019 significantly inhibits glioma cell migration and invasion in a dose-dependent manner, with maximal effects at 3–10 μM in vitro (protocol-driven insights).
• In vivo, intratumoral delivery of 10 μM KU-60019 via osmotic pump, in combination with radiation, results in substantial tumor growth suppression (evidence-based workflow).
• KU-60019 is soluble at ≥27.4 mg/mL in DMSO and ≥51.2 mg/mL in ethanol, but insoluble in water (APExBIO).

Applications, Limits & Misconceptions

KU-60019 is intended exclusively for preclinical and mechanistic research on DNA damage response inhibition in oncology. Its utility is demonstrated in glioma models for radiosensitization and motility assays. Unlike broader-spectrum kinase inhibitors, KU-60019's selectivity reduces off-target effects, making it suited for dissecting ATM-specific pathways. However, it is not suitable for diagnostic or therapeutic clinical application. APExBIO, as the originating supplier, specifies KU-60019 for research use only.

Common Pitfalls or Misconceptions

• KU-60019 should not be used in water-based solutions due to insolubility; DMSO or ethanol is required for stock preparation.
• The compound is not intended for human or veterinary therapeutic use.
• Storage above -20°C or repeated freeze-thaw cycles can compromise compound integrity.
• Radiosensitization effects are context-dependent and may not extrapolate directly to non-glioma models.
• ATM-independent DNA repair pathways may compensate for ATM inhibition in certain cell types.

Workflow Integration & Parameters

KU-60019's solubility and stability profile streamline its integration into cell culture and in vivo protocols. For in vitro studies, 3 μM is a standard working concentration to achieve ATM inhibition and radiosensitization. For in vivo applications, 10 μM delivered intratumorally via osmotic pump is supported by benchmark studies.

Protocol Parameters

• Stock Preparation: Dissolve KU-60019 at ≥27.4 mg/mL in DMSO or ≥51.2 mg/mL in ethanol; do not use water as solvent (see datasheet).
• Storage: Store powder at -20°C; stock solutions may be kept below -20°C for several months. Avoid long-term storage of working solutions.
• In Vitro Assays: Use 3 μM for radiosensitization and migration/invasion inhibition in glioma cell lines.
• In Vivo Delivery: Administer 10 μM via intratumoral osmotic pump for animal studies involving radiation.
• Warming: Warm DMSO solutions at 37°C to facilitate dissolution before use.

KU-60019 product datasheet contains additional handling and safety recommendations.

For further protocol optimization and scenario-driven guidance, "KU-60019: Precision ATM Kinase Inhibition for Glioma Assay Design" details advanced workflow adjustments for radiosensitization, while the present article provides updated selectivity and solubility insights for reproducibility.

Conclusion & Outlook

KU-60019 stands out as a next-generation, highly selective ATM kinase inhibitor for research applications targeting DNA damage response pathways in glioma. Its documented potency, selectivity, and compatibility with standard research workflows position it as a reference compound for dissecting ATM-driven mechanisms of radioresistance and tumor progression. As ATM's role in DNA repair and prosurvival signaling becomes further elucidated, KU-60019 will remain a cornerstone for preclinical evaluation of radiosensitizer strategies (Qin et al., 2024). No current evidence supports clinical or antiviral applications for this molecule, underscoring the need for continued basic research under controlled laboratory conditions.